Pacylex Pharmaceuticals Is Poised to Begin a Second Independent Clinical Trial for Its innovative Anti-Cancer Drug
Pacylex Pharmaceuticals plans to begin a second independent clinical trial of its anti-cancer drug, PCLX-001. The firm has recently been in the news for receiving FDA fast-track designation for PCLX-001 for treating relapsed or refractory acute myeloid leukemia (AML).
